Gastrointestinal Therapeutics Market Size is expected to register commendable growth between 2022 and 2028 owing to the surging demand for new therapies for a range of complex issues. Some of these include motility disorders, IBD, diarrheal disorders, constipation, iatrogenic diseases like visceral pain, postoperative ileus, GERD, and other esophageal disorders. Emerging sectors in the area of GI therapies include pharmacokinetics, special diets, opioid mechanisms of drug tolerance, and the interaction between gut microbiome and pharmacotherapy, microRNA’s, constipation, purinergic drugs, and others.
On the basis of product, the genetic segment is estimated to account for a lucrative share in the gastrointestinal therapeutics market through 2028. This is mainly attributed to an increase in the approval of genetic drugs for the treatment of GI disorders across various regions.
For instance, in December 2020, the U.S. Food and Drug Administration approved the first glucagon generic for injection USP for the treatment of very low blood sugar (severe hypoglycemia), which is likely to occur in patients having diabetes mellitus. The drug is also indicated as a diagnostic aid in the radiologic examination of the duodenum, stomach, and small bowel and colon.
Considering application, the gastrointestinal therapeutics market is expected to register appreciable gains from the ulcerative colitis segment up to 2028. The disease, which mainly impacts the mucosal lining of the colon, is a chronic idiopathic inflammatory disorder of the gastrointestinal tract. According to recent data, the prevalence of gastrointestinal diseases is increasing in numerous parts of the world owing to improved access to health, altered lifestyles, and improved rates of industrialization and sanitation. Presently, a number of institutes are exploring innovative and promising therapeutic approaches, which is expected to propel segment growth in the coming years.
Based on the regional landscape, the North America gastrointestinal therapeutics market is set to depict remarkable gains by 2028 owing to an increase in research activities across the region. Citing an instance, in October 2020, the University of California San Diego School of Medicine was named a top global university, with the divisions of Gastroenterology and Hepatology ranked for research. One of the studies performed in this institute deployed conventional versus investigational MRI (magnetic resonance imaging) for the purpose of monitoring and screening liver disease.
Some of the major players in the gastrointestinal therapeutics industry include Valeant Pharmaceuticals, Takeda Pharmaceuticals, Allergan plc, Bayer AG, Abbott Laboratories, AstraZeneca, GlaxoSmithKline plc, Janssen Pharmaceuticals, AbbVie Inc., Pfizer, and others. These companies are focusing on a range of strategic initiatives including partnerships, capacity expansion, mergers, partnerships, and innovative product launches for the expansion of their product portfolio.
For instance, in September 2021, Takeda Pharmaceutical Company Limited entered into an agreement for the divestment of a selection of non-core products from the company’s portfolio sold in Ecuador, Argentina, Panama, Colombia, Guatemala, Peru, Costa Rica, and other countries in the Caribbean and Central America.
The demand for gastrointestinal therapeutic drugs is set to be constant given the prevalence of GI symptoms through the diagnosis of COVID. This is because around 2% to 57% of patients experience GI complications owing to this infection. Commonly reported symptoms include vomiting, loss of appetite, loss of taste, nausea, abdominal pain, diarrhea, and others. The association of GI manifestations of SARS-CoV-2 with those exhibiting respiratory symptoms is expected to drive the demand for gastrointestinal therapeutic procedures.
The gastrointestinal therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:
Market, by Product
Market, by Route of Administration
Market, by Application
Market, by Distribution Channel
The above information is provided for the following regions and countries: